FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033838831> ?p ?o ?g. }

• W2033838831 endingPage "141" @default.
• W2033838831 startingPage "134" @default.
• W2033838831 abstract "Evidence indicates that angiotensin II type 2 receptors (AT2R) exert cerebroprotective actions during stroke. A selective non-peptide AT2R agonist, Compound 21 (C21), has been shown to exert beneficial effects in models of cardiac and renal disease, as well as hemorrhagic stroke. Here, we hypothesize that C21 may exert beneficial effects against cerebral damage and neurological deficits produced by ischemic stroke. We determined the effects of central and peripheral administration of C21 on the cerebral damage and neurological deficits in rats elicited by endothelin-1 induced middle cerebral artery occlusion (MCAO), a model of cerebral ischemia. Rats infused centrally (intracerebroventricular) with C21 before endothelin-1 induced MCAO exhibited significant reductions in cerebral infarct size and the neurological deficits produced by cerebral ischemia. Similar cerebroprotection was obtained in rats injected systemically (intraperitoneal) with C21 either before or after endothelin-1 induced MCAO. The protective effects of C21 were reversed by central administration of an AT2R inhibitor, PD123319. While C21 did not alter cerebral blood flow at the doses used here, peripheral post-stroke administration of this agent significantly attenuated the MCAO-induced increases in inducible nitric oxide synthase, chemokine (C-C) motif ligand 2 and C-C chemokine receptor type 2 mRNAs in the cerebral cortex, indicating that the cerebroprotective action is associated with an anti-inflammatory effect. These results strengthen the view that AT2R agonists may have potential therapeutic value in ischemic stroke, and provide the first evidence of cerebroprotection induced by systemic post stroke administration of a selective AT2R agonist." @default.
• W2033838831 created "2016-06-24" @default.
• W2033838831 creator A5000330838 @default.
• W2033838831 creator A5003921537 @default.
• W2033838831 creator A5004651591 @default.
• W2033838831 creator A5016627861 @default.
• W2033838831 creator A5028796118 @default.
• W2033838831 creator A5052836637 @default.
• W2033838831 creator A5061474894 @default.
• W2033838831 creator A5065721284 @default.
• W2033838831 creator A5068781595 @default.
• W2033838831 creator A5070331776 @default.
• W2033838831 creator A5079631959 @default.
• W2033838831 creator A5083197833 @default.
• W2033838831 date "2014-06-01" @default.
• W2033838831 modified "2023-10-18" @default.
• W2033838831 title "The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke" @default.
• W2033838831 cites W1485797085 @default.
• W2033838831 cites W1512110535 @default.
• W2033838831 cites W1517126484 @default.
• W2033838831 cites W1566795317 @default.
• W2033838831 cites W1973557056 @default.
• W2033838831 cites W1988502601 @default.
• W2033838831 cites W1994135647 @default.
• W2033838831 cites W2002169255 @default.
• W2033838831 cites W2002493104 @default.
• W2033838831 cites W2006922743 @default.
• W2033838831 cites W2007861988 @default.
• W2033838831 cites W2013900800 @default.
• W2033838831 cites W2016107840 @default.
• W2033838831 cites W2019305601 @default.
• W2033838831 cites W2029075996 @default.
• W2033838831 cites W2035615799 @default.
• W2033838831 cites W2041589863 @default.
• W2033838831 cites W2045075125 @default.
• W2033838831 cites W2047053137 @default.
• W2033838831 cites W2048851904 @default.
• W2033838831 cites W2052907531 @default.
• W2033838831 cites W2072749612 @default.
• W2033838831 cites W2079451588 @default.
• W2033838831 cites W2081572906 @default.
• W2033838831 cites W2085673586 @default.
• W2033838831 cites W2097867538 @default.
• W2033838831 cites W2098429613 @default.
• W2033838831 cites W2099769124 @default.
• W2033838831 cites W2101099825 @default.
• W2033838831 cites W2103776372 @default.
• W2033838831 cites W2121219041 @default.
• W2033838831 cites W2123247972 @default.
• W2033838831 cites W2125683177 @default.
• W2033838831 cites W2134840805 @default.
• W2033838831 cites W2137667272 @default.
• W2033838831 cites W2140474152 @default.
• W2033838831 cites W2151851600 @default.
• W2033838831 cites W2162189519 @default.
• W2033838831 cites W2162885610 @default.
• W2033838831 cites W2166615294 @default.
• W2033838831 doi "https://doi.org/10.1016/j.neuropharm.2014.01.044" @default.
• W2033838831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7472595" @default.
• W2033838831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24508710" @default.
• W2033838831 hasPublicationYear "2014" @default.
• W2033838831 type Work @default.
• W2033838831 sameAs 2033838831 @default.
• W2033838831 citedByCount "59" @default.
• W2033838831 countsByYear W20338388312014 @default.
• W2033838831 countsByYear W20338388312015 @default.
• W2033838831 countsByYear W20338388312016 @default.
• W2033838831 countsByYear W20338388312017 @default.
• W2033838831 countsByYear W20338388312018 @default.
• W2033838831 countsByYear W20338388312019 @default.
• W2033838831 countsByYear W20338388312020 @default.
• W2033838831 countsByYear W20338388312021 @default.
• W2033838831 countsByYear W20338388312022 @default.
• W2033838831 countsByYear W20338388312023 @default.
• W2033838831 crossrefType "journal-article" @default.
• W2033838831 hasAuthorship W2033838831A5000330838 @default.
• W2033838831 hasAuthorship W2033838831A5003921537 @default.
• W2033838831 hasAuthorship W2033838831A5004651591 @default.
• W2033838831 hasAuthorship W2033838831A5016627861 @default.
• W2033838831 hasAuthorship W2033838831A5028796118 @default.
• W2033838831 hasAuthorship W2033838831A5052836637 @default.
• W2033838831 hasAuthorship W2033838831A5061474894 @default.
• W2033838831 hasAuthorship W2033838831A5065721284 @default.
• W2033838831 hasAuthorship W2033838831A5068781595 @default.
• W2033838831 hasAuthorship W2033838831A5070331776 @default.
• W2033838831 hasAuthorship W2033838831A5079631959 @default.
• W2033838831 hasAuthorship W2033838831A5083197833 @default.
• W2033838831 hasBestOaLocation W20338388312 @default.
• W2033838831 hasConcept C126322002 @default.
• W2033838831 hasConcept C127413603 @default.
• W2033838831 hasConcept C134018914 @default.
• W2033838831 hasConcept C144980905 @default.
• W2033838831 hasConcept C157767197 @default.
• W2033838831 hasConcept C170493617 @default.
• W2033838831 hasConcept C2778938600 @default.
• W2033838831 hasConcept C2780645631 @default.
• W2033838831 hasConcept C2908929049 @default.
• W2033838831 hasConcept C42219234 @default.

• next